Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00263744 | Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive | PHASE1 | COMPLETED | 60 | — | — | Nov 1, 1999 | Jun 1, 2001 | Jan 8, 2009 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MEDI517 |
| 2 | ACTIVE_COMPARATOR | Aluminum hydroxide |
| Name | Type | Description |
|---|---|---|
| MEDI 517 | BIOLOGICAL | Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant. |
| Aluminum hydroxide | OTHER | Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL. |
Inclusion Criteria: * Female * 18 through 30 years of age (must not have reached the 31st birthday) * Unless previously surgically sterilized, agrees to use an effective method of birth control (e.g., abstinence, intrauterine contraceptive device, oral contraceptives, diaphragm or condom in combina...